New Jersey is currently home to 1701 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686
Recruiting
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
Register for Updates
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
NCT06742281
Recruiting
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 10016 healthy participants.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/30/2025
Locations: DM Clinical Research, Jersey City, New Jersey
Conditions: COVID-19
Register for Updates
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457
Recruiting
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps peop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: IMA Clinical Research-Warren-69742, Warren, New Jersey
Conditions: Metabolic Dysfunction Associated Steatohepatitis
Register for Updates
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286
Recruiting
The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with human immunodeficiency virus (PWH) who are virologically suppressed (HIV-1 RNA levels \< 50 copies/mL) on B/F/TAF for ≥ 6 months prior to screening. The primary objective is to evaluate the efficacy of switching to oral weekly ISL/LE... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: ID CARE, Hillsborough, New Jersey
Conditions: HIV-1-infection
Register for Updates
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543
Recruiting
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Capital Health Medical Center - Hopewell, Pennington, New Jersey
Conditions: Colorectal Cancer
Register for Updates
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772
Recruiting
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE). The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/30/2025
Locations: Sanmora Bespoke Clinical Research Solutions- Site Number : 8400015, East Orange, New Jersey
Conditions: Coeliac Disease, Celiac Disease
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/30/2025
Locations: Akero Clinical Study Site, Jackson, New Jersey
Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Register for Updates
A Study of Radiation Therapy After Surgery in People with Oral Tongue Squamous Cell Carcinoma
NCT06485778
Recruiting
This study will test whether limiting standard photon intensity modulated radiation therapy (IMRT) to exclude the oral tongue surgical site can decrease the risk of side effects caused by oral radiation. The researchers will also find out if this approach affects the rate of disease coming back after treatment (recurrence), and will measure participants' quality of life by having them complete questionnaires.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Oral Tongue Squamous Cell Carcinoma
Register for Updates
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Circuit Clinical, Secaucus, New Jersey
Conditions: Perennial Allergic Rhinitis (PAR)
Register for Updates
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299
Recruiting
This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Garden State Urology, Morristown, New Jersey
Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Register for Updates
Effects of Cycling and Virtual Reality on Thinking Speed in Persons With MS (PACE-MS)
NCT06191380
Recruiting
To compare the effects of cycling exercise with different types of virtual reality on processing/thinking speed in persons with multiple sclerosis (MS).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/30/2025
Locations: Kessler Foundation, East Hanover, New Jersey
Conditions: Multiple Sclerosis
Register for Updates
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821
Recruiting
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey
Conditions: CLL
Register for Updates